Serum Protein Profiling to Identify High-Risk Neuroblastoma: Preclinical Relevance of Blood-Based Biomarkers

Journal of Surgical Research

Volumn 142, Issue 2, 2007, Pages 268-274

  Sandoval, John A ^a   Turner, Katharyn E ^a   Hoelz, Derek J ^a   Rescorla, Frederick J ^a   Hickey, Robert J ^a   Malkas, Linda H ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

acute phase proteins response; animal model; high risk pediatric malignancy; neuroblastoma; serum proteomics

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA2 INTEGRIN; AMYLOID A PROTEIN; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; HAPTOGLOBIN; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER RISK; CHILD; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; KIDNEY; MASS SPECTROMETRY; MICE; MICE, NUDE; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PROTEOMICS; RISK FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548783245     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.03.058     Document Type: Article

References (36)

1. Brodeur G.M., and Castlebery R.P. Neuroblastoma. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and practice of pediatric oncology. 3rd ed. (1997), Lippincott, Philadelphia 761
2. Matthay K.K. Neuroblastoma. In: Pochedly C. (Ed). Neoplastic diseases in childhood (1994), Harwood, Chur, Switzerland 735
3. Kaneko M., Tsuchida Y., Uchino J., et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma. J Pediatr Hematol Oncol 21 (1999) 190
4. Sandoval J.A., Dobrolecki L.E., Huang J., et al. Neuroblastoma detection using serum proteomic profiling: A novel mining technique for cancer?. J Pediatr Surg 41 (2006) 639
5. Villanueva J., Philip J., Chaparro C.A., et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4 (2005) 1060
6. Rowe D.H., Huang J., Li J., et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35 (2000) 977
7. Sandoval J.A., Hoelz D.J., Woodruff H.A., et al. Novel peptides secreted from human neuroblastoma: Useful clinical tools?. J Pediatr Surg 41 (2006) 245
8. Mackiewicz A., and Mackiewicz K. Glycoforms of serum α-1 acid glycoprotein as markers of inflammation and cancer. Glycoconj J 12 (1995) 241
9. Hashimoto S., Asao T., Takahashi J., et al. α1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 101 (2004) 2825
10. Chawla R.K., Lawson D.H., Sarma P.R., et al. Serum α-1 proteinase inhibitor in advanced cancer: Mass variants and functionally inert forms. Cancer Res 47 (1987) 1179
11. Daddi G., and Mancini A. Increase of the α-1 antitrypsin in lung cancers. Boll Ist Sieroter Milan 55 (1976) 262
12. Tountas Y., Sparos L., Theodoropoulos C., et al. α-1 antitrypsin and cancer of the pancreas. Digestion 31 (1985) 37
13. Sukata T., Uwagawa S., Ozaki K., et al. α(2)-macroglobulin: A novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers. Am J Pathol 165 (2004) 1479
14. Ternell M., Moldawer L.L., Lonnroth C., et al. Plasma protein synthesis in experimental cancer compared to paraneoplastic conditions, including monokine administration. Cancer Res 47 (1987) 5825
15. Levo Y., Wollner S., and Treves A.J. Serum amyloid P-component levels in patients with malignancy. Scand J Immunol 24 (1986) 147
16. Kaneti J., Winikoff Y., Zimlichman S., et al. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 12 (1984) 239
17. Li J., Tan C., Xiang Q., et al. Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. J Protein Chem 20 (2001) 265
18. Tan C., Li J., Wang J., et al. Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection. Proteomics 2 (2002) 306
19. Shiyan S.D., and Bovin N.V. Carbohydrate composition and immunomodulatory activity of different glycoforms of α-1 acid glycoprotein. Glycoconj J 14 (1997) 631
20. Kawakami T., Hoshida Y., Kanai F., et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5 (2005) 4287
21. Ahmed N., Barker G., Oliva K.T., et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer 91 (2004) 129
22. Bharti A., Ma P.C., Maulik G., et al. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24 (2004) 1031
23. Smeets M.B., Fontijn J., Kavelaars A., et al. The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissues. Int J Exp Pathol 84 (2003) 69
24. Ang I.L., Poon T.C., Lai P.B., et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: A glycoproteomic approach. J Proteome Res 5 (2006) 2691
25. Okuyama N., Ide Y., Nakano M., et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 118 (2006) 2803
26. Biran H., Friedman N., Neumann L., et al. Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39 (1986) 794
27. Kimura M., Tomita Y., Imai T., et al. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 92 (2001) 2072
28. Cho W.C., Yip T.T., Yip C., et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10 (2004) 43
29. Chan D.C., Chen C.J., Chu H.C., et al. Evaluation of serum amyloid a as a biomarker for gastric cancer. Ann Surg Oncol 14 (2007) 84
30. Rosenthal C.J., and Sullivan L.M. Serum amyloid A to monitor cancer dissemination. Ann Intern Med 91 (1979) 383
31. Combaret V., Bergeron C., Brejon S., et al. Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett 228 (2005) 91
32. Koomen J.M., Shih L.N., Coombes K.R., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11 (2005) 1110
33. Francis D.M., Shenton B.K., Proud G., et al. Immunosuppressive plasma factors in malignant disease. Aust N Z J Surg 55 (1985) 111
34. Samak R., Edelstein R., and Israel L. Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer. Cancer Immunol Immunother 13 (1982) 38
35. Tilg H., Dinarello C.A., and Mier J.W. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol Today 18 (1997) 428
36. Nedelkov D., Kiernan U.A., Niederkofler E.E., et al. Population proteomics: The concept, attributes, and potential for cancer biomarker research. Mol Cell Proteomics 5 (2006) 1811